HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Glansbeek, H. L. Articles by Rottier, P. J. M. Search for Related Content PubMed PubMed Citation Articles by Glansbeek, H. L. Articles by Rottier, P. J. M. Agricola Articles by Glansbeek, H. L. Articles by Rottier, P. J. M.

Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus

Virology Division, Department of Infectious Diseases and Immunology, Veterinary Faculty, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands¹
Institute of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands²
Virbac Laboratories Inc., 06511 Carros Cedex, France³

Author for correspondence: Harrie Glansbeek. Fax +31 30 2536723. e-mail H.Glansbeek{at}vet.uu.nl

Cell-mediated immunity is thought to play a decisive role in protecting cats against feline infectious peritonitis (FIP), a progressive and lethal coronavirus disease. In view of the potential of DNA vaccines to induce cell-mediated responses, their efficacy to induce protective immunity in cats was evaluated. The membrane (M) and nucleocapsid (N) proteins were chosen as antigens, because antibodies to the spike (S) protein of FIP virus (FIPV) are known to precipitate pathogenesis. However, vaccination by repeated injections of plasmids encoding these proteins did not protect kittens against challenge infection with FIPV. Also, a prime–boost protocol failed to afford protection, with priming using plasmid DNA and boosting using recombinant vaccinia viruses expressing the same coronavirus proteins. Because of the role of IL-12 in initiating cell-mediated immunity, the effects of co-delivery of plasmids encoding the feline cytokine were studied. Again, IL-12 did not meet expectations – on the contrary, it enhanced susceptibility to FIPV challenge. This study shows that DNA vaccination failed to protect cats against FIP and that IL-12 may yield adverse effects when used as a cytokine adjuvant.

This article has been cited by other articles:

				B. J. Haijema, H. Volders, and P. J. M. Rottier Live, Attenuated Coronavirus Vaccines through the Directed Deletion of Group-Specific Genes Provide Protection against Feline Infectious Peritonitis J. Virol., April 15, 2004; 78(8): 3863 - 3871. [Abstract] [Full Text] [PDF]

				M. B. Gravenor, N. Stallard, R. Curnow, and A. R. McLean Repeated challenge with prion disease: The risk of infection and impact on incubation period PNAS, September 16, 2003; 100(19): 10960 - 10965. [Abstract] [Full Text] [PDF]

				E. M. A. van Rooij, H. L. Glansbeek, L. A. T. Hilgers, E. G. te Lintelo, Y. E. de Visser, W. J. A. Boersma, B. L. Haagmans, and A. T. J. Bianchi Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant J. Virol., September 11, 2002; 76(20): 10540 - 10545. [Abstract] [Full Text] [PDF]